Last reviewed · How we verify
Irinotecan Hydrochloride Injection(CAMPTO®) — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Irinotecan Hydrochloride Injection(CAMPTO®) (Irinotecan Hydrochloride Injection(CAMPTO®)) — Luye Pharma Group Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Irinotecan Hydrochloride Injection(CAMPTO®) TARGET | Irinotecan Hydrochloride Injection(CAMPTO®) | Luye Pharma Group Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Irinotecan Hydrochloride Injection(CAMPTO®) CI watch — RSS
- Irinotecan Hydrochloride Injection(CAMPTO®) CI watch — Atom
- Irinotecan Hydrochloride Injection(CAMPTO®) CI watch — JSON
- Irinotecan Hydrochloride Injection(CAMPTO®) alone — RSS
Cite this brief
Drug Landscape (2026). Irinotecan Hydrochloride Injection(CAMPTO®) — Competitive Intelligence Brief. https://druglandscape.com/ci/irinotecan-hydrochloride-injection-campto. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab